Articles

Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study

Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid
Division of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich
Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Massachusetts General Hospital, Boston, MA
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
Hospital General, Alicante
Department of Clinical Haematology, Centro Hospitalar e Universitário de Coimbra, Coimbra
Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Institute of Hematology and Blood Transfusion, Prague, Czech Republic
Department of Internal Medicine and Haematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Charles University Prague, Czech Republic
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
Division of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid
NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Haematologica Early view Aug 5, 2021 https://doi.org/10.3324/haematol.2021.278645